secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-04-02T23:59:59+00:00
Accession:  0001104659-25-031240
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma reports positive clinical data for QRX003: skin healed, no adverse events in pediatric Netherton patient
--------------------------------------------------------------------------------

- After 6 weeks of daily whole-body QRX003, the pediatric Netherton patient's skin is almost completely healed.
- Patient no longer requires antibiotics, antivirals, antihistamines, or glucocorticoids; pruritus eliminated.
- Zero nightly sleep disturbances without sedating medication; first continuous uninterrupted sleep in patient's life.
- No adverse events reported after 6 weeks of whole body treatment with QRX003.
- Company expects to initiate whole body application on a second pediatric patient in a few weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925031240/0001104659-25-031240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925031240/tm2511344d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-031240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer